MedTrace Logo

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

NCT01741831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2016-12-05

No results posted yet for this study

Summary

The purpose of this study is to assess the safety data of darunavir in a natural clinical practice.

Conditions

  • Acquired Immune Deficiency Syndrome

Interventions

DRUG

No intervention

This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd., Korea Clinical Trial · Janssen Korea, Ltd., Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741831 on ClinicalTrials.gov